Binimetinib Oral Tablet

DRUG2 trials

Sponsors

UNICANCER, Pierre Fabre Medicament

Conditions

BRAF V600 MutationBrain MetastasesMalignant MelanomaMelanomaMetastatic MelanomaUnresectable Melanoma

Phase 1

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Pierre Fabre MedicamentBRAF V600 Mutation, Melanoma, Metastatic Melanoma +1

Start: 2021-09-03End: 2021-11-29Updated: 2021-12-01

Phase 2

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Active, not recruitingNCT04074096

UNICANCERBRAF V600 Mutation, Brain Metastases, Malignant Melanoma

Start: 2022-09-05End: 2027-03-27Updated: 2026-06-05